Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (1815)	1/13/2012 10:57:59 AM
From: Biomaven	Respond to of 1834

Thanks BJ. In their JPM presentation, the company hinted that they had hopes the drug would actually be useful in schizophrenia aside from the movement disorder aspects. They said results from a 32 patient Phase II trial would be available soon. (It's a crossover trial, so 32 patients might be enough to get a decent read on efficacy here). If results are good, this could prove to be a significant asset for them. Peter